Loading

Review Article Open Access
Volume 6 | Issue 2 | DOI: https://doi.org/10.33696/cancerimmunol.6.088

Role of PD-L1 SP263 Assay in Cancer Immunotherapy: A Comprehensive Review

  • 1Department of Pathology, Tata Memorial Centre, Mumbai, India
  • 2Department of Laboratory Medicine, Dharamshila Narayana Super Speciality Hospital, New Delhi, India
  • 3Department of Histopathology and Cytology, Cytogenetics - Laboratory Medicine, Kokilaben Dhirubhai Ambani Hospital, Andheri Mumbai, India
  • 4Department of Pathology, Manipal Hospitals, Bengaluru, India
  • 5Department of Onco-Pathology, Homi Bhabha Cancer Hospital, Varanasi, India
  • 6Department of Medical, Scientific and Regulatory Affairs, Roche Diagnostics India, Mumbai, India
  • 7Department of Medical and Scientific Affairs, Roche Diagnostics India, Mumbai, India
+ Affiliations - Affiliations

Corresponding Author

Jayesh Deshmukh, jayesh.deshmukh@roche.com

Received Date: June 11, 2024

Accepted Date: July 15, 2024

Abstract

Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for many types of cancers, leading to significant improvements in patient survival. Treatments like nivolumab, pembrolizumab, durvalumab, and atezolizumab have shown remarkable efficacy. Among the various biomarkers used to guide ICI therapy, PD-L1 is one of the most extensively studied. The PD-L1 SP263 assay is one of the most commonly used assays for identifying PD-L1 status. The Food and Drug Administration has approved the PD-L1 SP263 (Ventana) assay as a companion diagnostic test for atezolizumab in early-stage NSCLC and cemiplimab-rwlc in advanced non-small cell lung cancer (NSCLC), thus offering a standardized method to predict patient responses to immunotherapy based on PD-L1 expression levels. It is the product indicated for use in NSCLC that has received Conformité Européenne marking for in vitro diagnostic (CE-IVD) designation as a companion diagnostic assay for treatment with four immunotherapeutic drugs (durvalumab, pembrolizumab, cemiplimab-rwlc, and atezolizumab) and as a complementary diagnostic assay for nivolumab. In this review, we have consolidated the findings about the PD-L1 SP263 assay, focusing on its use and methodology in NSCLC and other tumors. We discuss why the SP263 assay is important, how it compares with the 22C3 assay—the other widely used PD-L1 assay in NSCLC—and its effectiveness across various types of cancer. The PD-L1 SP263 assay has been used in multiple clinical trials (such as ARCTIC, PACIFIC, and IMpower series) to quantify PD-L1 expression. Concordance studies between the PD-L1 SP263 assay and other PD-L1 assays, especially the 22C3 assay, highlight the SP263 assay’s reliability and the potential for interchangeability when quantifying PD-L1 in NSCLC cases. Beyond NSCLC, the PD-L1 SP263 assay demonstrates clinical utility in gastric, hepatocellular, head and neck squamous cell, urothelial, and renal cell carcinomas. Additionally, this review discusses future directions, including utilizing artificial intelligence to enhance diagnostic accuracy and predict treatment responses, thereby optimizing personalized cancer care.

Keywords

Cancer immunotherapy, PD-L1, Diagnostic assay, Clinical utility, Immune checkpoint inhibitor (ICI), SP263, Non-small cell lung cancer (NSCLC)

Author Information X